(-)-phenmetrazine | 497180-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (-)-phenmetrazine
• 英文别名: (2R,3R)-3-methyl-2-phenylmorpholine
• CAS: 497180-74-2
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: OOBHFESNSZDWIU-KOLCDFICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (-)-phenmetrazine 生成 L-3-Methyl-2-phenyl-4-(1-phenyl-propyl-(2)-amino)-morpholin
  参考文献：
  名称：

  4-Aminomorpholines¹

  摘要：

  DOI：

  10.1021/jm00334a007
• 作为产物：
  描述：

  1-苯基-2-甲基-3-氮杂-1,5-戊烷二醇 在 氢溴酸 作用下， 反应 3.0h， 生成 (-)-phenmetrazine
  参考文献：
  名称：

  4-Aminomorpholines¹

  摘要：

  DOI：

  10.1021/jm00334a007

文献信息

• [EN] TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS<br/>[FR] LE CIBLAGE DE LA THYMIDYLATE KINASE HUMAINE INDUIT UNE TOXICITÉ DANS LA RÉPARATION DE L'ADN DANS LES CELLULES TUMORALES MALIGNES
  申请人：CHANG ZEE-FEN

  公开号：WO2012072019A1

  公开（公告）日：2012-06-07

  The present invention relates to novel TMPK inhibitor compositions and their methods of use. In particular, it relates to novel TMPK inhibitor compositions and therapeutics that lead to dUTP-mediated DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.

  本发明涉及新型TMPK抑制剂组合物及其使用方法。具体而言，涉及新型TMPK抑制剂组合物和导致肿瘤细胞中dUTP介导的DNA修复的治疗剂，作为新型化疗增敏剂，适用于治疗或预防癌症的方法。
• Dihydropyrimidinone derivatives
  申请人：KING SAUD UNIVERSITY

  公开号：US10111873B1

  公开（公告）日：2018-10-30

  A dihydropyrimidinone derivative having a chemical structure according to Formula 1: wherein Z is selected from N and O; X is selected from O and S; and R represents aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the substituted aryl or substituted heteroaryl have one or more substituents selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, hydroxyl, alkylthio, alkylamino, heteroaryl, aryloxy, haloaryloxy, arylthio, arylamino, and pharmaceutically acceptable salts thereof.

  一种二氢嘧啶酮衍生物，其化学结构如公式1所示：其中Z选自N和O；X选自O和S；而R代表芳基，取代芳基，杂环芳基或取代杂环芳基，其中取代芳基或取代杂环芳基具有一个或多个取代基，所述取代基选自卤素，烷基，卤代烷基，烷氧基，卤代烷氧基，硝基，羟基，烷硫基，烷基氨基，杂环芳基，芳基氧基，卤代芳基氧基，芳基硫基，芳基氨基和其药学上可接受的盐。
• [EN] HYDROGEN PEROXIDE SENSORS BASED UPON PHOTO-INDUCED ELECTRON TRANSFER<br/>[FR] DÉTECTEURS DE PEROXYDE D’HYDROGÈNE BASÉS SUR LE TRANSFERT D’ÉLECTRONS PAR PHOTO-INDUCTION
  申请人：OPTI MEDICAL SYSTEMS

  公开号：WO2011011605A1

  公开（公告）日：2011-01-27

  The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+. The invention also provides methods of detecting and determining the presence of analytes and/or hydrogen peroxide in a sample, as well as a substrate that comprises the compound of formula I.

  该发明提供了I式化合物F-L-Q（I），其中F包括一种荧光团，能够在激发波长吸收能量，并在缺乏淬灭剂的情况下，在发射波长发射能量，该发射波长不同于激发波长；Q包括一种淬灭剂；L包括一个连接基团，具有两个末端，其中一个末端与F共价结合，另一个末端与Q共价结合。这些化合物能够进行可逆反应（1），如下所示：（1）其中Q +是Q的氧化形式，表示没有淬灭剂，Ox包括一种氧化剂，能够将Q氧化为其氧化形式Q，而Red包括一种还原剂，能够将Q转化回其还原形式Q。当受到能量辐射并且Q存在于其氧化形式Q +时，这些化合物可以进行光诱导电子转移。该发明还提供了检测和确定样品中分析物和/或过氧化氢存在的方法，以及包含I式化合物的基板。
• Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
  申请人：Pharmacia Corporation

  公开号：US20040176378A1

  公开（公告）日：2004-09-09

  The present invention provides compositions and methods for the treatment of reduced blood flow to the central nervous system in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition comprising the administration to a subject of an amphetamine in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了一种用于治疗主体中心神经系统血流量减少的组合物和方法。更具体地，本发明提供了一种中枢神经系统缺血症的组合治疗方法，包括向主体注射苯丙胺和环氧合酶-2选择性抑制剂。
• PHENYLMORPHOLINES AND ANALOGUES THEREOF
  申请人：Blough Bruce E.

  公开号：US20130203752A1

  公开（公告）日：2013-08-08

  Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

  本文提供了化合物和前药，以及制备这些化合物和前药的方法，这些化合物和前药能够作为单胺神经递质，包括多巴胺、血清素和去甲肾上腺素的释放剂和/或摄取抑制剂发挥作用。还提供了包含这些化合物或前药中的一个或多个的药物组合物，该组合物可能进一步包含一个或多个额外的治疗药物。还提供了治疗各种可能对单胺神经递质水平修正敏感的疾病的方法，例如肥胖前期、肥胖、成瘾和抑郁症。